Shire is a biotechnology company that researches, develops, licenses, manufactures, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The Company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Shire markets its products through wholesalers, distributors, and various pharmacies.
TypePublic
HQDublin, IE
Founded1986
Size (employees)23,044 (est)-3%
Websiteshire.com
Shire was founded in 1986 and is headquartered in Dublin, IE
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Shire

Flemming Ornskov

Flemming Ornskov

CEO
Thomas Dittrich

Thomas Dittrich

CFO
Andreas Busch

Andreas Busch

Head of Research and Development and Chief Scientific Officer
Bill Mordan

Bill Mordan

General Counsel and Company Secretary
Joanne Cordeiro

Joanne Cordeiro

Chief Human Resources Officer
Perry Sternberg

Perry Sternberg

Head of US Commercial
Show more

Shire Office Locations

Shire has offices in Hanoi, Guaynabo, Cambridge, Bannockburn and in 48 other locations
Dublin, IE (HQ)
50 Baggot Street Lower
Sydney, AU
225 George St
Wien, AT
67 Industriestraße
Bruxelles, BE
47 Rue Montoyer
Chácara Santo Antonio (Zona Sul), BR
Av. das Nações Unidas, 14.171
Sofia, BG
2 2a ul. "Saborna"
Show all (53)
Report incorrect company information

Shire Financials and Metrics

Shire Revenue

Shire's revenue was reported to be £52.26 m in FY, 2017 which is a 39.3% increase from the previous period.
USD

Market capitalization (18-Oct-2018)

54.0b

Closing stock price (18-Oct-2018)

177.0
Shire's current market capitalization is $54 b.
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.5m4.7m14.1m18.2m26.5m19.2m20.1m29.0m32.4m119.6m108.0m98.3m114.0m111.4m103.4m109.3m120.6m122.3m67.1m58.2m47.6m52.3m

Revenue growth, %

(9%)16%(2%)(7%)6%10%1%(45%)9467%70%39%

Operating expense total

6.0m6.5m13.9m20.4m27.2m32.6m36.3m39.1m41.8m101.5m159.8m95.1m100.7m104.7m106.5m113.1m120.3m123.2m70.1m55.9m46.4m5.3b

Depreciation and amortization

1.2b1.8b
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.5b1.6b1.7b1.7b2.4b3.5b3.6b3.7b3.5b

Cost of goods sold

227.8m228.0m262.7m248.6m778.1m1.7b1.3b1.1b1.0b

Gross profit

1.3b1.3b1.4b1.5b1.7b1.7b2.2b2.6b2.5b

Gross profit Margin, %

85%85%84%85%68%50%63%70%72%
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.7k219.3k17.0k4.0k135.5m528.8m472.4m

Accounts Receivable

5.0k4.0k1.2b2.6b3.0b

Prepaid Expenses

197.4m806.3m795.3m

Inventories

455.3m544.8m635.4m3.6b3.3b
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

74.3m64.0m44.9m69.0m693.4m728.6m369.0m263.7m209.3m

Accounts Receivable

1.1b1.1b1.3b1.3b2.4b2.6b2.6b2.8b2.8b

Prepaid Expenses

216.6m221.6m215.0m314.4m733.6m665.3m787.2m778.5m779.9m

Inventories

588.7m632.8m608.9m680.0m5.8b4.9b3.3b3.3b3.4b
Annual
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(939.6k)(1.9m)1.2m(762.0k)(179.0k)(12.2m)(9.8m)(15.1m)(10.5m)5.7m(65.5m)7.5m15.1m4.7m(1.9m)(2.7m)1.6m1.6m(2.9m)2.9m2.5m3.1m

Depreciation and Amortization

324.4m407.3m637.2m1.5b2.3b

Inventories

(63.2m)(255.8m)(145.1m)

Accounts Payable

109.2m621.6m(526.8m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

410.4m570.0m1.0b419.0m256.9m(129.9m)375.0m615.3m1.2b

Depreciation and Amortization

120.6m291.8m457.4m168.9m429.8m877.8m486.9m1.0b1.6b

Inventories

(22.0m)(37.4m)(21.7m)(32.2m)(116.4m)(228.0m)(151.8m)(171.6m)(245.2m)

Accounts Payable

77.5m(39.8m)56.5m(154.6m)342.7m315.2m(671.5m)(445.1m)(557.8m)
Show all financial metrics

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Phase Approved

2 3 4 7
Show all operating metrics

Shire Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
BaxaltaJanuary 11, 2016$32 b
DyaxNovember 02, 2015$5.90 b
Foresight BiotherapeuticsAugust 03, 2015$300 m
Meritage PharmaFebruary 24, 2015$245 m
NPS Pharmaceuticals, Inc.January 11, 2015$5.20 b
Lumena PharmaceuticalsMay 13, 2014$260 m
Fibrotech TherapeuticsMay 02, 2014$75 m
ViroPharma IncorporatedNovember 11, 2013$4.20 b
SARcode BioscienceMarch 25, 2013$160 m
PremacureMarch 12, 2013
Show more

Shire Revenue Breakdown

Embed Graph

Shire revenue breakdown by business segment: 11.6% from Internal Medicine, 30.2% from Immunology, 18.4% from Neuroscience, 10.0% from Genetic Diseases, 26.2% from Hematology and 3.6% from Other

Human Capital Metrics

Shire's employees are reported to be approximately 52% female and 48% male.
Embed Graph
Show all human capital metrics
Report incorrect company information

Shire Online and Social Media Presence

Embed Graph
Report incorrect company information

Shire News and Updates

Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks

CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks

Takeda gets Japanese approval for $62 billion Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc , bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

UPDATE 1-Takeda gets Japanese approval for $62 bln Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Takeda gets Japan's approval for $62 billion Shire purchase

(Reuters) - Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Takeda gets Japan's approval for $62 bln Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Takeda's $62 billion Shire bid faces November 6 EU antitrust deadline

EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion takeover of London-listed Shire Plc , the European Commission said on Friday.
Show more
Report incorrect company information

Shire Company Life and Culture

Report incorrect company information